Preparation of exenatide-loaded linear poly(ethylene glycol)-brush poly(l-lysine) block copolymer: potential implications on diabetic nephropathy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 30 citations in OpenAlex.

1. A study to evaluate the impact of PB-119 injection (a pegylated exenatide formulation) on the pharmacokinetic profiles of Digoxin and Warfarin sodium in healthy subjects.SAGE open medicine · 2026
   Article
2. Nanotherapeutics in Kidney Disease: Innovations, Challenges, and Future Directions.Journal of the American Society of Nephrology : JASN · 2025
   Review
3. Nanofiber matrix formulations for the delivery of Exendin-4 for tendon regeneration:Bioactive materials · 2023
   Article
4. Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics.Acta pharmaceutica Sinica. B · 2022
   Review
5. A Conserved Hydrophobic Moiety and Helix-Helix Interactions Drive the Self-Assembly of the Incretin Analog Exendin-4.Biomolecules · 2021
   Article
6. Primary and Secondary Binding of Exenatide to Liposomes.Biophysical journal · 2020
   Article
7. Phycocyanin/PEG-International journal of nanomedicine · 2019
   Article
8. Lumbrokinase/paclitaxel nanoparticle complex: potential therapeutic applications in bladder cancer.International journal of nanomedicine · 2018
   Article
9. Endogenous ornithine decarboxylase/polyamine system mediated the antagonist role of insulin/PEG-CMCS preconditioning against heart ischemia/reperfusion injury in diabetes mellitus.International journal of nanomedicine · 2018
   Article
10. In vitro/vivo drug release and anti-diabetic cardiomyopathy properties of curcumin/PBLG-PEG-PBLG nanoparticles.International journal of nanomedicine · 2018
    Article
11. Quercetin nanoparticle complex attenuated diabetic nephropathy via regulating the expression level of ICAM-1 on endothelium.International journal of nanomedicine · 2017
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as